Prostate Biopsy — Procedure Guide, Recovery & Risks | MyMedicPlus

A prostate biopsy is the definitive diagnostic procedure for prostate cancer, obtaining core tissue samples from the prostate gland for histopathological examination. It is performed when PSA (prostate-specific antigen) blood levels are elevated, when a suspicious lesion is identified on multiparametric MRI (mpMRI), or when a digital rectal examination reveals an abnormal prostate texture. Two main approaches are in clinical use: transperineal (TP) biopsy, performed through the perineal skin under local anaesthesia or sedation, and transrectal ultrasound (TRUS) biopsy, performed through the rectal wall. Transperineal biopsy has become the preferred technique at most specialist centres due to its significantly lower risk of septic complications. MRI-fusion guided biopsy combines pre-procedure mpMRI images with real-time ultrasound to precisely target suspicious lesions within the gland, improving cancer detection accuracy. Systematic biopsy of non-targeted areas is also performed to ensure complete gland sampling. Prostate biopsy is the definitive diagnostic test for prostate cancer, involving systematic sampling of prostate tissue using a hollow-core needle under imaging guidance. The most common approach is transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, in which cores are taken from a standardised template spanning the base, mid, and apex in the lateral and medial regions bilaterally. Multiparametric MRI (mpMRI) of the prostate before biopsy — the MRI-first pathway endorsed by NICE NG131 and EAU guidelines — identifies PI-RADS 3–5 lesions requiring targeted biopsy in addition to systematic cores, improving clinically significant cancer detection rates and reducing overdiagnosis of low-risk disease. Transperineal biopsy, performed via skin of the perineum rather than through the rectum, offers significantly lower infection risk (sepsis rate under 0.1% vs 1–3% for transrectal) and is increasingly adopted as the preferred approach.

Prostate biopsy is indicated when the PSA level is elevated for age (generally above 3 ng/mL in men under 70 years, or above 4 ng/mL in older men), following PSA velocity trending upward over serial measurements, or when mpMRI of the prostate identifies a PI-RADS 3, 4, or 5 lesion. National guidelines (EAU, NCCN) recommend mpMRI before biopsy to guide sampling towards clinically significant disease and to avoid biopsying when MRI is normal (PI-RADS 1–2) in lower-risk presentations. Repeat biopsy is indicated when an initial negative biopsy fails to explain a persistently elevated PSA, particularly if a suspicious mpMRI lesion was not adequately sampled. Contraindications include uncontrolled coagulopathy, active urinary tract infection, and uncorrected anticoagulation. Patients on antiplatelet agents or anticoagulants require bridging or cessation protocols discussed with their prescribing physician.

Transperineal biopsy is performed with the patient in the lithotomy position. After local anaesthetic injection into the perineal skin and prostate base, a fine-gauge needle is inserted through the perineum under transrectal ultrasound guidance. Targeted biopsies are taken from mpMRI-identified lesions using cognitive or software-based MRI-TRUS fusion techniques; systematic biopsies sample 12 or more cores from the left and right lobes in a grid pattern. The procedure takes 30–45 minutes. Transrectal biopsy, performed through the rectal wall after antibiotic prophylaxis, uses a spring-loaded biopsy needle with ultrasound guidance; it is increasingly replaced by the transperineal approach at specialist centres. Biopsy cores are preserved in formalin-filled containers labelled by anatomical location and sent to the pathology laboratory. A haematologist reporting the biopsies grades cancer using the International Society of Urological Pathology (ISUP) Grade Group system based on Gleason scoring. Transrectal TRUS biopsy is performed with the patient in the left lateral decubitus position after cleansing enemas. A TRUS probe is inserted rectally, providing real-time ultrasound guidance. Local anaesthetic (lidocaine) is injected into the periprostatic space (periprostatic nerve block) to reduce pain. An 18G spring-loaded biopsy needle fires through the rectal wall into the prostate, obtaining 12 systematic cores from a standardised template plus targeted cores from MRI-identified PI-RADS 3–5 lesions. For transperineal (TP) biopsy, the patient is in lithotomy position; after perineal and periprostatic local anaesthetic, a template grid guides systematic biopsies through the perineal skin — 20–30 cores from a 5-mm template grid, or 3D mapping biopsy for comprehensive sampling. TP biopsy requires general or spinal anaesthesia or sedation in most centres. Procedure duration is 10–20 minutes for TRUS, 30–45 minutes for TP template biopsy.

Prostate biopsy is the only means of definitively diagnosing prostate cancer, grading its aggressiveness, and selecting appropriate management. MRI-targeted transperineal biopsy detects clinically significant prostate cancer (Grade Group 2 or above, Gleason 7 or above) in 40–50% of biopsied men with PI-RADS 4–5 lesions. In men with PI-RADS 1–2 scans, the risk of clinically significant cancer is below 10%, allowing many to avoid unnecessary biopsy. The PRECISION trial demonstrated that mpMRI-directed transperineal biopsy detected 38% more clinically significant cancers and 89% fewer clinically insignificant cancers than systematic TRUS biopsy alone, substantially reducing overdiagnosis. Accurate Gleason grading from biopsy directly determines treatment: active surveillance for Grade Group 1–2, radical prostatectomy or radiotherapy for Grade Group 3–5. Prostate biopsy, when guided by mpMRI (MRI-targeted plus systematic), detects 20–30% more clinically significant prostate cancer (Gleason grade group 2 and above) and 10–15% less clinically insignificant cancer (Gleason grade group 1) compared to systematic biopsy alone. MRI-targeted biopsy reduces the number of cores needed and minimises complications. Transperineal biopsy essentially eliminates sepsis risk compared to transrectal approach, a clinically important advantage in an era of increasing fluoroquinolone antibiotic resistance.

Haematuria (blood in urine) occurs in virtually all patients after transperineal biopsy and typically resolves within 3–5 days. Haematospermia (blood in semen) persists for 4–6 weeks in the majority and is harmless but distressing. Haematochezia (rectal bleeding) is specific to transrectal biopsy and is usually self-limiting. Perineal bruising and discomfort after transperineal biopsy resolves over 5–10 days. Urinary retention requiring temporary catheterisation occurs in 2–5% of patients. Serious infection (sepsis) is the most feared complication of TRUS biopsy, occurring in 1–3% due to inoculation of rectal bacteria into the prostate; transperineal biopsy reduces sepsis risk to under 0.1%, a major safety advantage. Antibiotic prophylaxis (single-dose ciprofloxacin or fosfomycin) is given regardless of route. Very rarely, significant haemorrhage requires hospital admission.

After transperineal biopsy under local anaesthesia, patients are monitored in the day unit for 1–2 hours to ensure voiding and that haematuria is not excessive. They are discharged home with written post-biopsy instructions. Adequate oral hydration (2–3 litres daily) reduces the concentration of blood in the urine and lowers infection risk. Strenuous exercise, cycling, and sexual activity are avoided for 5–7 days. Anticoagulant or antiplatelet medications that were paused pre-procedure are restarted after 24–48 hours, guided by the pre-procedure protocol. Patients are advised to seek urgent review if they develop fever above 38.5°C, rigors, difficulty passing urine, or heavy or persistent bleeding — these may indicate infection or urinary retention. Biopsy results are typically available within 7–14 days and are discussed at a follow-up consultation with the urologist.